If approved, it will be the Thousand Oaks-based biotech giant’s first new drug on the market since the FDA’s landmark approval of the first-ever biosimilar drug on the American market.
With California in the midst of some of its driest months on record, the statewide drought is far from over, and one Westlake Village firm is looking to bring farmers some solutions.
On March 9, a company memo announced its plans to shutter San Francisco facilities once belonging to Onyx Pharmaceuticals and lay off 300 employees there.
Real estate developer and art collector William Rolland is pledging up to $4 million to California Lutheran University for a new art department building. According to the university, CLU will cover the remaining $4 million needed to fund the development of a 25,000- to 30,000-square-foot art center on the Thousand Oaks campus to be named Read More →
Amgen, the nation’s biggest biotech company, reported fourth-quarter profits that beat analysts’ estimates, aided by a tax benefit and higher-than-estimated sales of arthritis drug Enbrel.
On the back of its strong financial performance in 2014, Amgen, the Tri-Counties’ largest private employer, is set to begin shifting research operations away from its Thousand Oaks headquarters.
